Relay Therapeutics (RLAY) Projected to Post Earnings on Wednesday

Relay Therapeutics (NASDAQ:RLAY) is anticipated to release its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect Relay Therapeutics to post earnings of ($0.38) per share for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 26, 2026 at 4:00 PM ET.

Relay Therapeutics Trading Down 1.8%

Shares of RLAY stock opened at $8.70 on Monday. The stock has a market capitalization of $1.51 billion, a price-to-earnings ratio of -4.97 and a beta of 1.59. Relay Therapeutics has a 12-month low of $1.77 and a 12-month high of $9.54. The stock’s 50-day moving average price is $8.26 and its 200-day moving average price is $6.55.

Insiders Place Their Bets

In other news, CEO Sanjiv Patel sold 43,168 shares of Relay Therapeutics stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $7.82, for a total transaction of $337,573.76. Following the completion of the sale, the chief executive officer directly owned 661,041 shares in the company, valued at approximately $5,169,340.62. This trade represents a 6.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Thomas Catinazzo sold 13,820 shares of the business’s stock in a transaction on Tuesday, January 27th. The shares were sold at an average price of $7.62, for a total transaction of $105,308.40. Following the sale, the chief financial officer directly owned 250,996 shares of the company’s stock, valued at $1,912,589.52. This represents a 5.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 93,302 shares of company stock worth $724,355 in the last 90 days. 4.32% of the stock is owned by insiders.

Institutional Investors Weigh In On Relay Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Marshall Wace LLP bought a new position in shares of Relay Therapeutics during the 2nd quarter worth $179,000. Creative Planning raised its holdings in shares of Relay Therapeutics by 214.1% in the second quarter. Creative Planning now owns 72,618 shares of the company’s stock valued at $251,000 after acquiring an additional 49,501 shares in the last quarter. Jane Street Group LLC lifted its stake in Relay Therapeutics by 47.6% in the first quarter. Jane Street Group LLC now owns 111,472 shares of the company’s stock worth $292,000 after acquiring an additional 35,962 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Relay Therapeutics by 6.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 84,069 shares of the company’s stock worth $221,000 after acquiring an additional 5,238 shares in the last quarter. Finally, CIBC Bancorp USA Inc. bought a new position in Relay Therapeutics during the 3rd quarter worth about $74,000. Institutional investors own 96.98% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on RLAY shares. Oppenheimer raised Relay Therapeutics from a “market perform” rating to an “outperform” rating and set a $14.00 price objective on the stock in a research note on Monday, January 26th. Wells Fargo & Company upgraded shares of Relay Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $6.00 to $13.00 in a research report on Friday, December 12th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Relay Therapeutics in a research note on Friday, January 9th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $16.57.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.